Controlling inflammation and cellular damage is the key to preventing and treating multiple organ failure and death associated with sepsis and septic shock. Despite improvements in our understanding of mechanisms underlying sepsis and its complications, there are currently no drugs approved to specifically treat severe sepsis. Our overarching goal is ultimately to develop new therapeutics for sepsis patients based on our identification of regulatory mechanisms of inflammation during sepsis that may serve as promising drug targets. In this proposal we will investigate novel roles for inducible nitric oxide synthase (iNOS) and nitric oxide (NO) during sepsis. NO and iNOS are integral components of host responses to pathogens, and have been shown to have protective effects in organs such as the liver during sepsis. We have had a long-standing interest in the role of iNOS/NO particularly in the liver, and how these effects can be protective during sepsis. In this grant application we propose to investigate the pathways that transmit signals from bacterial components, through pattern recognition and cytokine receptors, such as Toll-like receptors (TLR) and IL1- receptor, to regulate iNOS expression and lead to the cleavage of a soluble cytokine receptor, TNFR1, from the cell surface of hepatocytes. Our preliminary data has identified a key novel role for TLR/IL1R-mediated iNOS in activating the enzyme responsible for cleavage of TNFR1, TNF-converting enzyme (TACE or ADAM17). Activation of TACE and release of TNFR1 are important mechanisms in regulating the inflammatory effects of the cytokine TNF, high levels of which have been associated with increased organ damage and patient death during sepsis. Our data are novel in that they describe a specific effect of iNOS-upregulation and a novel, unexpected feedback of NO on iNOS to regulate receptor shedding, as well as an important novel role for iNOS as part of the activating complex of proteins at the cell surface in both human and mouse liver. Understanding the role of iNOS in the regulation of TNFR1 release may ultimately result in development of drugs designed to specifically affect these pathways to improve patient outcome during sepsis.
Our specific aims are to determine the role of Myddosome-signaling via TLR/IL1R in iNOS regulation and TNFR1-shedding from hepatocytes and liver during sepsis, and also determine how iNOS activates TACE to allow a complex to form at the cell surface to cleave TNFR1 in the liver and hepatocytes. We will also investigate whether iNOS regulates other TACE-mediated functions during sepsis, and what the specific role for iNOS is within the TACE/TNFR1 complex at the cell surface. Our experiments will allow us to clearly identify the effects of the novel TLR-iNOS-mediated pathways important in regulating inflammation and organ damage during sepsis.

Public Health Relevance

Sepsis is still a major cause of morbidity and mortality, and despite improvements in our understanding of the mechanisms involved in inflammation and organ damage, there are currently no drugs approved to treat severe sepsis. Our proposal investigates novel pathways of inflammation regulated by inducible nitric oxide synthase (iNOS) and nitric oxide (NO), known mediators of protective responses during sepsis, and the regulation of the inflammatory cytokine TNF, which has been shown to correlate with severity of sepsis. Our long term goal is to develop new therapies to treat patients with sepsis and inflammation based on our improved understanding of the cellular pathways involved.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM044100-24A1
Application #
8691050
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Somers, Scott D
Project Start
1990-04-01
Project End
2018-03-31
Budget Start
2014-05-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
$298,272
Indirect Cost
$103,272
Name
University of Pittsburgh
Department
Surgery
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Deng, Wenjun; Zhu, Shan; Zeng, Ling et al. (2018) The Circadian Clock Controls Immune Checkpoint Pathway in Sepsis. Cell Rep 24:366-378
Li, Wenbo; Zhang, Wei; Deng, Meihong et al. (2018) Stearoyl Lysophosphatidylcholine Inhibits Endotoxin-Induced Caspase-11 Activation. Shock 50:339-345
Lei, Zhao; Deng, Meihong; Yi, Zhongjie et al. (2018) cGAS-mediated autophagy protects the liver from ischemia-reperfusion injury independently of STING. Am J Physiol Gastrointest Liver Physiol 314:G655-G667
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Wang, Ronghua; Li, Yawen; Tsung, Allan et al. (2018) iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway. Proc Natl Acad Sci U S A 115:E10127-E10136
Zhou, Hui; Deng, Meihong; Liu, Yingjie et al. (2018) Platelet HMGB1 is required for efficient bacterial clearance in intra-abdominal bacterial sepsis in mice. Blood Adv 2:638-648
Zeng, Ling; Kang, Rui; Zhu, Shan et al. (2017) ALK is a therapeutic target for lethal sepsis. Sci Transl Med 9:
Xu, Hui; Turnquist, Heth R; Hoffman, Rosemary et al. (2017) Role of the IL-33-ST2 axis in sepsis. Mil Med Res 4:3
Wang, Qingde; Li, Xiaoni; Qi, Ruofan et al. (2017) RNA Editing, ADAR1, and the Innate Immune Response. Genes (Basel) 8:
Davila-Gonzalez, Daniel; Chang, Jenny C; Billiar, Timothy R (2017) NO and COX2: Dual targeting for aggressive cancers. Proc Natl Acad Sci U S A 114:13591-13593

Showing the most recent 10 out of 60 publications